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Summary
Roflumilast is a selective phosphodiesterase 4 inhibitor
which has been licensed in the European Union since 2010
and in Switzerland since November 2011 as an add-on
treatment for patients with chronic obstructive pulmonary
disease (COPD) in GOLD (Global Initiative for Chronic
Obstructive Lung Disease) stages 3 and 4 (FEV1 <50% pre-
dicted after bronchodilatation) and frequent exacerbations
despite correctly-dosed therapy with a long-acting bron-
chodilator. Roflumilast is designed to target both the sys-
temic and pulmonary inflammation associated with COPD.
In this review roflumilast’s chemistry, pharmacodynamics,
pharmacokinetics, clinical efficacy, safety and tolerability
and the current ongoing clinical trials involving roflumilast
are outlined. Information has been sourced from the Swiss
and US product information monographs, peer-reviewed
published literature (identified from a PubMed MEDLINE
search 1966 – March 2012 using the term “roflumilast”),
the COPD GOLD international guidelines for the manage-
ment of COPD (Revised 2011) and an independent analys-
is of phase 3 clinical trial data by FDA staff physicians.
Clinical efficacy in terms of a modest gain in FEV1% and
a reduction in exacerbation rate has been demonstrated in
phase 3 clinical trials and roflumilast has been recently
incorporated into international treatment guidelines.
However data examining roflumilast as add-on therapy to
long-acting bronchodilators and ICS (standard therapy) is
currently awaited and phase 4 post-marketing studies are
required to determine the incidence and severity of adverse
events and the long-term beneficial effects of roflumilast
as a maintenance therapy for COPD in every-day clinical
practice.
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Introduction
The burden of the chronic obstructive pulmonary disease
(COPD) is increasing worldwide (www.goldcopd.com).
The prevalence in Switzerland, for instance, has been es-
timated to be 2–7% of the population depending on age and
gender [1] and as many as twenty-eight per cent of cur-
rent smokers suffer from COPD [2]. In 2004 COPD was
the fourth leading cause of death world-wide [3].
COPD is characterised by irreversible chronic airflow lim-
itation that usually leads to a progressive decline in lung
function over time. The development of COPD is associ-
ated with both chronic airway and systemic inflammation
[4, 5]. Effective treatment of COPD is based on a combin-
ation of smoking cessation, physical activity and pharma-
cological agents. The aim of pharmacotherapy is to reduce
symptoms, reduce the frequency and severity of exacer-
bations and improve health status and exercise tolerance
[6]. Pharmacological treatment centres essentially around
short-acting bronchodilators for patients in low risk cat-
egories through long-acting bronchodilators and inhaled
corticosteroids to most recently, add-on therapy with the
phosphodiesterase-4 (PDE4) inhibitor roflumilast [6].
Theophylline, a non-specific phosphodiesterase inhibitor,
is also licensed for the treatment of COPD, however its
usefulness in clinical practice is restricted by adverse ef-
fects, limited efficacy and its potential for drug interac-
tions. Its use has therefore declined in recent years [7].
Roflumilast has been called a “designer” theophylline by
some [8].
However, none of the established pharmacological treat-
ments for COPD, either alone or in combination, have been
shown to ameliorate the progressive decline in lung-func-
tion or to decrease mortality [9, 10]. There is therefore a
great need for new agents such as roflumilast which may
show disease-modifiying effects. A further recent develop-
ment in the management of COPD has been the more indi-
vidualised approach to pharmacological treatment through
more accurate phenotyping [6], which promotes the need
for more accurate phenotyping methods [11].
Compared to previous guidelines, the recent global
guidelines for the management of COPD promote a more
individual tailoring of pharmacological therapy according
to symptoms (classified as “less” and “more”), air-flow
limitation (classified as “mild”, “moderate”, “severe” and
“very severe”, GOLD stages 1–4 respectively), risk of ex-
acerbation (classified as “low”: ≤1 exacerbation per year
and “high”: ≥2 exacerbations per year) and the presence
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of co-morbidities. Patients are then grouped according to
these three aspects into one of four groups labelled A, B, C
or D. Treatment recommendations are made on the basis of
the group into which the patient falls [6]. Whether this new
approach will improve guideline-conformity among treat-
ing physicians, however, remains to be seen [12].
Roflumilast and its main metabolite roflumilast N-oxide
are selective PDE4 inhibitors which act to decrease im-
mune and inflammatory cell activation [13, 14]. Roflu-
milast was developed, patented and marketed by Nycomed
GmbH (Germany) and was licensed in the European Union
in July 2010 and in Switzerland in November 2011 as an
add-on treatment for patients with GOLD stages 3 and 4
(FEV1 <50% predicted after bronchodilatation) and fre-
quent exacerbations despite correctly-dosed therapy with
a long-acting bronchodilator. Roflumilast is marketed in
Switzerland by Nycomed Pharma AG (Dübendorf,
Switzerland) under the name Daxas®. In the United States
of America, roflumilast was granted Food and Drug Ad-
ministration [15] approval in February 2011 and is mar-
keted by Forest Pharmaceuticals Inc. (St. Louis) as Da-
liresp®. Roflumilast is licensed in the USA “as a treatment
to reduce the risk of COPD exacerbations in patients with
severe COPD associated with chronic bronchitis and a his-
tory of exacerbations” [16]. Chronic bronchitis is defined
as the presence of cough and sputum production for at least
3 months in each of 2 consecutive years [6]. According
to the current GOLD COPD guidelines, roflumilast should
be considered as add-on therapy to inhaled corticosteroids
(ICS) and long-acting beta2 agonist (LABA) in combina-
tion or with a long-acting anticholinergic alone for patients
with more symptoms, high risk of exacerbation and severe
or very severe airflow limitation (“group D” patients) [6].
For patients with less symptoms but otherwise the same
characteristics (“group C” patients), roflumilast is recom-
mended as an alternative choice to standard first-line ther-
apy with ICS and LABA or LAMA. Roflumilast is the first
and only PDE4 inhibitor currently licensed for use in hu-
mans and the current licensed indication is tightly specified
[17], however further applications, such as in the treatment
of asthma, are being investigated [18, 19]. The licensed
dose is 500 µg in tablet form orally once daily with or
without food.
In this review we outline roflumilast’s chemistry, phar-
macodynamics, pharmacokinetics, clinical efficacy, safety
and tolerability and the current ongoing clinical trials. In-
formation has been sourced from the Swiss and US product
information monographs, peer-reviewed published literat-
ure (identified from a PubMed MEDLINE search 1966
– March 2012 using the term “roflumilast”), the COPD
GOLD international guidelines for the management of
COPD (Revised 2011) [6] and the independent analysis of
phase 3 clinical trial data by FDA staff physicians [15].
Chemistry
The chemical name of roflumilast is N-(3,
5-dichloropyridin-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxy-
benzamide. Its empirical formula is C17H14Cl2F2N2O3 and
its molecular weight is 403.2 g/mol [16].
Pharmacodynamics
Roflumilast’s mechanism of action is to increase cAMP
levels in eosinophils, monocytes and neutrophils through
selective, competitive inhibition of PDE4. This is achieved
by the failure of PDE4, when inhibited, to inactivate cAMP
[20]. Increased cAMP levels in these inflammatory cells
reduces their activation, thereby attenuating the inflam-
matory response [14]. PDE4 is also expressed in airway
smooth muscle cells, however an acute bronchodilatory
effect of PDE4 inhibition has not been confirmed [21].
This fact is explicitly outlined in the product information
which warns against the use of roflumilast for the relief
of acute bronchospasm [16, 22]. Roflumilast is therefore
a non-steroid, anti-inflammatory agent designed to target
both the systemic and pulmonary inflammation associated
with chronic obstructive pulmonary disease. The pre-clin-
ical pharmacology of roflumilast has recently been brought
together in an extensive review by Hatzelmann and col-
leagues [13]. A previously trialled PDE4 inhibitor cilom-
ilast showed extensive gastrointestinal side effects (primar-
ily nausea and vomiting) mediated by inhibition of the
PDE4 subtype D, for which roflumilast shows a lower
affinity [8]. The anti-inflammatory effects of
PDE4-inhibitors appear to be mediated by inhibition of the
PDE4B subtype, for which roflumilast has a higher affinity
than cilomilast [8].
In a randomised, double-blind, placebo-controlled, cros-
sover study to assess the anti-inflammatory potential of ro-
flumilast in moderate-to-severe COPD patients (n = 38)
significant reductions in absolute numbers of sputum eos-
inophils (–50%, p <0.001), neutrophils (–35.5%, p = 0.002)
and lymphocytes (–34.8%, p = 0.022) were found [23].
However, a non-significant reduction in the percentage of
neutrophils making up the total sputum cell-count was
found. Other inflammatory markers in sputum or plasma
(studied as secondary endpoints) also showed significant
reductions in roflumilast-treated subjects and both pre- and
post-bronchodilator FEV1 increased (79.5 and 68.7ml re-
spectively, p <0.001 and p <0.018). The authors concluded
that the improvement in lung function seen was likely due
in part to roflumilast’s anti-inflammatory effects.
The product information for Daliresp® further references a
study by Hohlfeld and colleagues in 37 healthy volunteers
who received 28 days of roflumilast 500 µg once daily or
placebo in a randomised, double-blind manner [16, 24]. A
baseline bronchoalveolar lavage was then performed and
the volunteers underwent segmental pulmonary endotoxin
challenge with lipopolysaccharide followed by repeat bron-
choscopy and segmental lavage 24 hours later. Subjects
who had been pre-treated with roflumilast showed reduced
total cell-, neutrophil- and eosinophil- influx compared to
placebo (statistically significant differences of 36%, 39%
and 74% respectively).
Pharmacokinetics
After oral dosing, roflumilast is rapidly and almost entirely
absorbed with maximum plasma concentrations being
reached within approximately one hour (range 0.5–2 hours)
in healthy volunteers [16, 25]. The absolute bioavailability
Review article Swiss Med Wkly. 2012;142:w13628
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 9
following oral administration is 79% [26]. After systemic
uptake, roflumilast is extensively bound to plasma proteins
(99%) and distributed with a volume of distribution of ap-
proximately 2.9 L/kg [27]. Roflumilast is metabolised by
both phase I (cytochrome P450 – CYP) and phase II (con-
jugation) reactions. In vitro studies and clinical drug in-
teraction studies have shown that roflumilast is primarily
metabolised via CYP 3A4 and 1A2 to roflumilast N-oxide.
In humans, roflumilast N-oxide is the most important meta-
bolite. The plasma area under the time-concentration curve
for roflumilast N-oxide is 10-fold greater than for roflu-
milast (table 1). So, despite being 3-fold less potent than
roflumilast in terms of PDE4 inhibition (measured by total
inhibitory PDE4 activity – tPDE4i), roflumilast N-oxide is
thought to account for the majority of the pharmacologic-
al effects seen [27]. Roflumilast and roflumilast N-oxide
show dose-proportional, linear pharmacokinetic properties,
whereby doubling the dose results in a doubling of peak
concentrations and AUCs for both substances [25].
Roflumilast N-oxide is metabolised by CYP3A4 and 2C19
or glucuronidated to inactive metabolites [7]. Extensive
in vitro studies using human hepatic microsomes did not
show any inhibition of CYP1A2, 2A6, 2C9, 2C19, 2D6,
2E1, 3A4/5 or 4A9/11 by roflumilast or roflumilast N-ox-
ide at therapeutic concentrations. A weak induction of CYP
2B6 activity was shown for roflumilast [22]. Inactive roflu-
milast metabolites are excreted to a large extent in the urine
(70% of a radioactively labelled oral or intravenous roflu-
milast dose administered to human subjects was recovered
in the urine and 20% in faeces) [22].
Pharmacokinetic parameters of roflumilast and roflumilast
N-oxide are summarised in table 1.
Drug-drug interactions
Being substrates for CYP 3A4, 1A2 and 2C19, the phar-
macokinetics (and therefore efficacy and toxicity) of roflu-
milast and roflumilast N-oxide are subject to a number of
drug-drug interactions. Due to the formation of the active
metabolite roflumilast N-oxide by CYP3A4, the effect of
CYP3A4 inhibition or induction is not straight-forward to
predict. Pharmacokinetic drug-drug interaction studies are
therefore best interpreted in light of changes in tPDE4i –
a measure of the total PDE4 inhibitory activity – as this
reflects the overall pharmacodynamic effect of inhibiting
or inducing roflumilast and roflumilast N-oxide’s metabol-
ism. The derivation of the parameter tPDE4i is beyond the
scope of this review, but can be found in the current product
information for Daxas® [22] or in a recent book chapter by
Tenor and colleagues [27].
While there are no contraindicated drug-drug combinations
with roflumilast, the product information draws special at-
tention to the interactions with inhibitors of CYP 3A4 or
dual inhibitors of CYP3A4 and 1A2 (erythromycin, keto-
conazole, fluvoxamine, enoxacin – a fluoroquinolone not
licensed in Switzerland – and cimetidine) which “will in-
crease roflumilast systemic exposure and may result in in-
creased adverse reactions. The risk of such a concurrent
use should be weighed carefully against benefit” [16]. Sim-
ilarly the use of strong CYP inducers (e.g., rifampicin,
phenobarbital, cabamazepine and phenytoin) is not recom-
mended [16]. Data from drug-drug interaction studies with
CYP inhibitors and inducers are shown in table 2. A study
of the effects of cigarette smoke on roflumilast pharma-
cokinetics showed no interaction [28]. Interaction studies
with warfarin, inhaled budesonide, oral montelukast, in-
haled salbutamol, inhaled formoterol, oral theophylline and
an antacid containing magnesium hydroxide and alumini-
um hydroxide similarly showed no significant changes in
roflumilast pharmacokinetics [28]. Midazolam (a CYP3A4
substrate) and digoxin (a P-glycoprotein substrate) showed
no alteration in their pharmacokinetic characteristics when
co-administered with roflumilast in steady state indicating
that roflumilast itself does not affect the activity of
CYP3A4 or P-glycoprotein [29, 30]. Sildenafil, a
PDE5-inhibitor and weak CYP 1A2, 2C19 and 3A4 inhib-
itor does not interact significantly with roflumilast and no
dose-adjustments are necessary [16].
Special populations (hepatic
impairment, renal impairment,
pregnancy, children and adolescents,
elderly, gender, race, smoking)
Being metabolised in the liver, the pharmacokinetics of ro-
flumilast are affected by liver disease. A study of patients
with mild hepatic impairment (n = 8 patients with Child-
Pugh A cirrhosis) showed a 51% increase in the roflumilast
AUC and a 24% increase in the roflumilast N-oxide AUC
when compared with sex, age and body-weight matched
healthy controls who also received roflumilast 250 µg for
14 days (n = 8). For patients with moderate hepatic impair-
ment (n = 8 with Child-Pugh B cirrhosis), AUC for roflu-
milast and roflumilast N-oxide were 92% and 41% higher
than for the healthy controls respectively [31]. Roflumilast
is therefore contraindicated in patients with Child-Pugh B
Table 1: Pharmacokinetic data for roflumilast and roflumilast N-oxide.
Parameter Roflumilast Roflumilast N-oxide Reference
Bioavailability ~80% – [26]
Protein binding 99% 97% [25]
Volume of distribution (L/kg) 2.9 [22]
Peak concentration range (µg/l) 5.3–8.3 8.8–13.1 [7]
Median time to peak concentration (h)* 1 (range 0.5–2) 8 (4–13) [22]
Mean half-life (h) 17 30 [22]
Clearance (l/h)** 9.6 [22]
AUC0-∞ range (mg*h/l) 31–61 350–646 [7]
Time until steady state (days) 4 6 [22]
* in fasting state
** following a short intravenous infusion
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or C hepatic impairment and caution is advised with pa-
tients with Child-Pugh A hepatic impairment [22].
Severe renal impairment (creatinine clearance <30 ml/min)
was found to be associated with minor decreases in the
AUC of roflumilast and roflumilast N-oxide when com-
pared with healthy controls who were also administered ro-
flumilast 500 µg once daily [32]. There were no signific-
ant differences in safety and tolerability between the two
groups (n = 12 for each). The product information does not
advise dosage adjustment for patients with renal impair-
ment. Although not yet studied, the high protein binding of
roflumilast and roflumilast N-oxide (table 1) are likely to
preclude roflumilast from effective removal by haemodia-
lysis.
The use of roflumilast in pregnancy and breast-feeding is
not licensed in Switzerland. Furthermore, women of child-
bearing age should use a reliable method of contraception.
In the US product information, roflumilast is categorised
as FDA “Pregnancy Category C” which is defined as fol-
lows: “Either studies in animals have revealed adverse ef-
fects on the fetus [teratogenic or embryocidal or other] and
there are no controlled studies in women or studies in wo-
men and animals are not available. Drugs should be given
only if the potential benefit justifies the potential risk to the
fetus.” [33]. Roflumilast is not licensed for breast-feeding
women. Roflumilast has been shown to cross the placenta
and to enter breast milk in animal studies.
Roflumilast is not currently licensed for use in children and
adolescents. However, if the licensed indication for roflu-
milast is to be extended to the treatment of asthma in the
future, pharmacokinetic data in children and adolescents
are required. To date a single study examining the pharma-
cokinetics, safety and tolerability of roflumilast single 100
µg or 250 µg doses in a cross-over open-label design in 13
children (age 6–7) and 12 adolescents (age 11–16) has been
published [34]. The authors conclude that the exposure of
roflumilast in children appears to be similar to that seen
in adults and that roflumilast was well tolerated. However,
further studies are required to assess the pharmacokinetics
and pharmacodynamics of roflumilast following single and
multiple doses in children with asthma.
Studies comparing the pharmacokinetics of roflumilast and
roflumilast N-oxide in persons > and <65 years of age,
in men and women, in Caucasians, African Americans,
Hispanics and Japanese as well as in smokers and non-
smokers concluded that no dosage adjustments are neces-
sary in these groups [16].
Clinical efficacy
The clinical efficacy of roflumilast in the treatment of mod-
erate to severe COPD has been studied in a series of large
placebo-controlled trials called “RECORD” (M2-107),
“OPUS” (M2-111), “RATIO” (M2-112), “HERO”
(M2-121), “AURA” (M2-124), “HERMES” (M2-125),
“EOS” (M2-127) and “HEILOS” (M2-128) (table 3).
Primary end points were mainly changes in lung function,
rates of exacerbation and health-related quality of life. The
US product information cites data from two dose-finding
studies (one of which M2-107), four 1-year placebo-con-
trolled trials (M2-111, M2-112, M2-124 and M2-125) and
two 6-month trials examining the effect of roflumilast as
add-on therapy to long-acting bronchodilators (M2-127
and M2-128) [16] while the Swiss product information
cites data from M2-124, M2-125, M2-127 and M2-128
[22].
As shown in table 3, all studies consistently showed statist-
ical improvement in pre- and/or post-bronchodilator FEV1,
however there was inconsistency in the effect of roflumilast
on exacerbation rate and quality of life. Drug-related unde-
sired effects were recorded in all studies.
In interpreting these findings, the FDA Medical review
states the following: “The difference in study designs and
use of concomitant medications used to treat COPD make
inter-study comparisons difficult. It should be noted that
in no study was the efficacy of roflumilast evaluated com-
pared to what has become standard of care treatment for
patients with severe COPD, concomitant use of a LABA,
LAMA, and an inhaled corticosteroid” [15].
Bateman and colleagues have recently performed a pre-
specified, additional, pooled analysis of M2-124 and
M2-125 looking at the efficacy and safety of roflumilast
used concomitantly with long-acting beta agonists (LABA)
to reduce exacerbations and the influence of exacerbation
history on the response to roflumilast. The effect of roflu-
milast was compared in patients using and not using LABA
and exacerbation rate was found to be reduced irrespect-
ive of concomitant LABA use. A significant increase in
time to first exacerbation, however, was only seen as a
whole for patients concomitantly treated with roflumilast
and LABA. There were no additional safety concerns re-
garding the use of roflumilast in conjunction with a LABA.
Previous exacerbation history appeared to be associated
with the response to roflumilast with frequent exacerbators
(≥2 exacerbations in preceding year) experiencing a great-
er reduction in moderate or severe exacerbations (rate ra-
tio 0.78, 95% CI 0.66–0.91, p = 0.002) than infrequent ex-
acerbators (rate ratio 0.835, 95% CI 0.73–0.95, p = 0.0062)
[35].
Table 2: Summary of cytochrome P450-related drug-drug interaction studies.
Drug (affected CYP) Conditions* Total PDE4 inhibitory activity Reference
Erythromycin (3A4 inhibitor) Single dose roflumilast, erythromycin in steady state +9% [40]
Ketoconazole (3A4 inhibitor) Single dose roflumilast, ketoconazole in steady state +9% [41]
Eonxacin (1A2 inhibitor) Single dose roflumilast, enoxacin in steady state +25% [42]
Cimetidine (1A2, 2C19, 3A4 inhibitor) Single-dose roflumilast, cimetidine in steady state +48% [43]
Fluvoxamine (1A2, 2C19, 3A4 inhibitor) Single dose roflumilast, fluvoxamine in steady state +59% [44]
Rifampicin (2C19 and 3A4 inducer) Single dose roflumilast, rifampicin in steady state –58% [45]
* Roflumilast dose always 500 µg.
** Ideally roflumilast will not be given in this context.
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Table 3: Phase 3 randomised, double-blind, placebo controlled multi-centre clinical trials of roflumilast in moderate to severe COPD.
Study names Patients, mean post-
bronchodilator FEV1
% predicted
Treatments Duration
(study years)
Primary end
points
Primary end
point
reached?
Secondary end points Secondary end point
reached?
RECORD
M2 – 107 [36]
1,411, 54% ROF 250 µg
ROF 500 µg
PB
Plus SABA and/or
SAAC as required
6 months
(2002–2003)
A. Change in
post-
bronchodilator
FEV1*
B. Change in
SGRQ
A. Yes:
250 µg + 74
ml, 500 µg +
97 ml (p
<0.0001)
B. No
A. Pre-bronchodilator FEV1*
B. Mean number of
exacerbations per patient**
A. Yes:
250 µg + 64 ml (p =
0.0006), 500 µg +88
ml (p <0.0001)
B. Placebo 1.13,
250 µg 1.03
500 µg 0.75
OPUS
M2-111
Not published
but data made
available to
FDA [15]
1,176, ≤50%
Smoking history of
≥10 pack years
ROF 500 µg
PB
Plus SABA as
required and
continued ICS (%
unknown)
12 months
(2003–2005)
A. Change in
pre-
bronchodilator
FEV1*
B. Rate of
moderate or
severe
exacerbations
per patient per
year
A. Yes: + 36 ml
(p = 0.003)
B. No:
exacerbation
rate ratio 0.865
(p = ns)
A. Change in post
bronchodilator FEV1
B. Number of moderate or
severe exacerbations per patient
per year in different subgroups
(FEV1 <30%, with chronic
bronchitis ± emphysema, cough
score >1 or >2, h/o moderate or
severe COPD exacerbations
A. Yes + 38 ml (p =
0.0002)
B. Yes for patients
with mean sputum
score >2 (rate ratio
ROF/PB 0.615, p =
0.03) and for patients
with mean cough
score ≥2 (rate ratio
ROF/PB 0.615, p =
0.03).
RATIO
M2-112 [46]
1,513, 41% ROF 500 µg
PB
Plus SABA as
required and in
65% continued
ICS
12 months
(2003–2004)
A. Change in
post-
bronchodilator
FEV1*
B. Number of
moderate or
severe
exacerbations
per patient per
year§
A. Yes
+ 39 ml
(p = 0.001)
B. No
A. Improvement in SGRQ
B. Pre-bronchodilator FEV1*
C. Exacerbations according to
GOLD stage
A. No
B. Yes + 36 ml
(p <0.002)
C. GOLD Stage IV
exacerbation rate
reduced, rate ratio
ROF/PB 0.639 (p =
0.024)
RATIO and
OPUS pooled
analysis [17]
2,686, all ≤50% ROF 500 µg
PB
Plus SABA as
required and
continued ICS
(61% ROF and
60% PB )
12 months
(2003–2005)
Rate of moderate or severe
exacerbations per patient per
year**
Exacerbation rate
ratio ROF/PB 0.897 (p
= 0.026)
HERO
M2-121
Not published
but data made
available to
FDA [15]
Unknown, ≤65% ROF 500 µg
PB
6 months A. Change in
post-
bronchodilator
FEV1*
B. FRC
(functional
residual
capacity)
To our
knowledge not
publicly
available
AURA
M2-124
[38]
1,523, 38% with at
least 1 exacerbation
requiring systemic
corticosteroids and/or
hospitalisation within
the last year
ROF 500 µg
PB
Plus LABA and/or
SABA and/or
SAAC as required
12 months
(2006–2008)
A. Change in
pre-
bronchodilator
FEV1*
B. Rate of
moderate or
severe acute
exacerbations**
A. Yes + 39 ml
(p = 0.0003)
B. Yes:
exacerbation
rate ratio 0.85
(p = 0.03)
A. Change in post-
bronchodilator FEV1*
B. Time to death from any cause
C. C-reactive protein
concentration
D. Transition Dyspnea Index
focal score
A. Yes + 49 ml
(p <0.0001)
B. No
C. No
D. Yes: difference 0.2
(p = 0.04)
HERMES
M2-125
[38]
1,568, 35% with at
least 1 exacerbation
requiring systemic
corticosteroids and/or
hospitalisation within
the last year
ROF 500 µg
PB
Plus LABA and/or
SABA and/or
SAAC as required
12 months
(2006–2008)
A. Change in
pre-
bronchodilator
FEV1*
B. Rate of
moderate or
severe acute
exacerbations**
A. Yes + 58 ml
(p <0.0001)
B. Yes:
exacerbation
rate ratio 0.82
(p = 0.004)
A. Change in post-
bronchodilator FEV1*
B. Time to death from any cause
C. C-reactive protein
concentration
D. Transition Dyspnea Index
focal score
A. Yes + 61 ml
(p <0.0001)
B. No
C. No
D. Yes: difference 0.3
(p = 0.006)
EOS
M2-127
[47]
933, 55% ROF 500 µg
PB
Plus Salmeterol
6 months
(2006–2008)
A. Change in
pre-
bronchodilator
FEV1*
A. Yes + 49 ml
(p <0.0001)
A. Post-bronchodilator FEV1
B. Post-bronchodilator FVC*
C. Transition dyspnea index
score
D. Shortness of breath
questionnaire
E. Use of short acting
bronchodilators
F. Exacerbation rates (all types)
A. Yes + 60ml
(p <0.0001)
B. Yes + 58 ml
(p 0.003)
C, D, E, F No
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HELIOS
M2-128
[47]
743, 56% plus
presence of chronic
cough and frequent
use of short acting
bronchodilators
ROF 500 µg
PB
Plus Tiotropium
6 months
(2006–2008)
A. Change in
pre-
bronchodilator
FEV1*
A. Yes + 80 ml
(p <0.0001)
A. Post-bronchodilator FEV1
B. Post-bronchodilator FVC*
C. Transition dyspnea index
score
D. Shortness of breath
questionnaire
E. Use of short-acting
bronchodilators
F. Exacerbation rates (all types)
A. Yes + 81 ml
(p <0.0001)
B. Yes + 101 ml
(p = 0.0004)
C. Yes: Difference 0.4
(p = 0.003)
D. Yes: Difference
–2.6 (p = 0.005)
E. Yes: Difference
–0.51 (p = 0.0004)
F. No
* value is the difference between placebo and treatment changes in spirometry parameters from baseline
** moderate exacerbations = treatment with systemic corticosteroids, severe exacerbations = exacerbation requiring hospitalisation and/or leading to death
§ Moderate exacerbations = symptomatic deteriorations treated with systemic corticosteroids and/or antibiotics, severe exacerbations = those requiring hospitalisation.
FEV1 = forced expiratory volume in 1 second, PB = placebo, ROF = roflumilast, SAAC = short-acting anticholinergic, SABA = short-acting beta-2 agonist, SGRQ = St
George’s respiratory questionnaire.
Safety and tolerability
The FDA has published data from a pooled analysis of
COPD studies obtained from 14 placebo-controlled Phase
2 and 3 studies which comprise the so called “COPD safety
pool”. This pool includes approximately 12000 patients
with COPD of which more than half received roflumilast.
With regard to dose and duration of exposure, 5766 (88%)
received the proposed, once daily regimen of 500 µg oral
roflumilast, 797 (12%) received roflumilast 250 µg.
Among those who received 500 µg roflumilast, 1,232 were
treated for at least one year, 1,081 for 6 months to less
than 1 year, 2,081 for 3 to less than 6 month and 1,370
for less than 3 months. The median duration of exposure
with 500 µg roflumilast was 167 days [15]. The most com-
mon adverse effect of roflumilast is diarrhoea (10.1% in
the groups treated with roflumilast 500 µg/d compared with
2.6% in the placebo arms) (table 4). Other adverse events
are also shown in table 4. Adverse events were found to oc-
cur mainly within the first weeks of therapy and resolved
during continued treatment [27].
A few key areas in the safety and tolerability of roflumilast
which require special attention have emerged: gastrointest-
inal effects, weight loss, psychiatric disturbance (including
suicide) and possible carcinogenesis [15]. These adverse
effects are uncommon to existing COPD therapies and pa-
tients require close monitoring, particularly during the
early phases of treatment with roflumilast.
Gastrointestinal adverse events
Gastrointestinal adverse events are an established class ef-
fect of PDE4 inhibitors. Vomiting has only rarely been seen
with roflumilast (≤1%) [36]; the main events are diarrhoea
Table 4: Adverse event frequency: analysis of pooled data [15, 28]. All adverse events occurring at a frequency ≥2% in patients treated with roflumilast are listed.
Adverse event Placebo (n = 5491) Roflumilast 500 µg (n = 5,766)
All adverse events (%) 3,447 (62.8) 3,873 (67.2)
Patients with serious adverse events (%) 782 (14.2) 781 (13.5)
Deaths (%) 86 (1.6) 84 (1.5)
Adverse events with suggested causality as judged by investigator 294 (5.4) 1,003 (17.4)
Study discontinued due to adverse events 503 (9.2) 824 (14.3)
Infections and infestations
Nasopharyngitis
Bronchitis
Upper respiratory tract infection
Pneumonia
Influenza
1,508 (27.5)
346 (6.3)
192 (3.5)
234 (4.3)
110 (2)
132 (2.4)
1,492 (25.9)
364 (6.3)
177 (3.1)
219 (3.8)
104 (1.8)
145 (2.5)
Gastrointestinal disorders
Diarrhoea
Nausea
143 (2.6)
79 (1.4)
585 (10.1)
297 (5.2)
Investigations
Weight decreased 101 (1.8) 394 (6.8)
Respiratory, thoracic and mediastinal disorders
COPD
Dyspnoea
1,271 (23.1)
120 (2.2)
1,142 (19.8)
84 (1.5)
Musculoskeletal and connective tissue disorders
Back pain 117 (2.1) 176 (3.1)
Nervous system disorders
Headache
Dizziness
110 (2.0)
65 (1.2)
266 (4.6)
139 (2.4)
Metabolism and nutrition disorders
Decreased appetite 22 (0.4) 125 (2.2)
Psychiatric disorders
Insomnia 50 (0.9) 148 (2.6)
Vascular disorders
Hypertension 136 (2.5) 95 (1.6)
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and nausea – a likely consequence of which being de-
creased appetite (table 4).
Weight loss
Weight loss is an adverse event not previously associated
with PDE4 inhibitors. It is a relevant event as lower body
mass is associated with a poorer prognosis in COPD pa-
tients [37]. In M2-124 and M2-125, the mean weight
change was a reduction of 2.09 kg (SD 3.98) in the
roflumilast-treated arm after 1 year and an increase of 0.08
kg (3.48) in the placebo arm. The largest absolute weight
loss with roflumilast was seen in obese patients (BMI >30).
The change in weight in the roflumilast arm occurred dur-
ing the first 6 months of treatment and showed an associ-
ation with the presence of gastrointestinal symptoms and
headache [38], however this is unlikely to account entirely
for the weight loss seen. A direct lipolytic effect of roflu-
milast has been proposed [28].
The Swiss product information makes further note of the
reversibility of weight loss on stopping roflumilast – in
M2-124 and M2-125 patients attained their baseline weight
3 months after stopping roflumilast. Doctors should keep a
close eye on their patients’ weight and patients should be
encouraged to weigh themselves every two weeks.
Psychiatric effects
Insomnia is the most common psychiatric adverse event re-
ported (2.6% in the pooled safety data – table 4). Other re-
ported effects are anxiety states and depression. The US
product information notes three cases of suicide-related ad-
verse reactions (one completed suicide) while receiving ro-
flumilast in clinical trials compared to one patient with sui-
cidal ideation who received placebo. The Swiss product in-
formation mentions rare cases of suicidal ideation under ro-
flumilast and, like the American product information warns
against its use in patients with a past history of suicidal
ideation resulting from depression [16, 22]. Data reported
by the FDA show 3 completed and 2 attempted suicides
among roflumilast-treated and none among placebo-treated
study participants [15]. Causality was however not com-
mented upon [15]. Post-marketing data for roflumilast is
limited and being a new drug, subject to reporting bias.
Nonetheless, in 2011, 16 cases of suicidal ideation, 3 cases
of attempted suicide and 2 cases of completed suicide were
reported to the Uppsala Monitoring Centre World Health
Organization collaborating Centre for International Drug
Monitoring (VigiBaseTM Services. www.umc-
products.com Date last accessed 13. March 2012, search
terms “Roflumilast” and “Psychiatric disorders”). To date
in 2012, 4 cases of suicidal ideation, 1 case of attempted
suicide and 1 case of completed suicide have been reported
to the same organisation. Causality assessments are not
given so the relationship between these events and roflu-
milast cannot be commented upon and would require inde-
pendent, expert review.
Malignancy
Whether roflumilast is associated with malignancy or not
is currently a topic of debate [39]. Roflumilast has been
found to be carcinogenic in animal (rodent) studies [15]. In
the pooled safety analysis by the FDA, tumours were found
in 1.5% of the roflumilast-treated subjects and 1.3% of the
placebo-treated subjects. There were significant increases
in lung, prostate, and colorectal cancers in the roflumilast
treated COPD patients compared to placebo [15]. Com-
parison with age-matched non-COPD cohorts has not been
made. The majority of tumours were solid tumours, which
are known to develop slowly over several years and the ma-
jority, were diagnosed during the first 6 months of treat-
ment, with no difference between placebo- and roflumilast-
treated subjects after 6 months of treatment, suggesting
against a causal relationship with roflumilast [28].
Contraindications
The current listed contraindications to roflumilast therapy
are hypersensitivity to roflumilast or one of the compon-
ents of Daxas® and moderate to severe liver impairment
(Child-Pugh class B or C) [22].
Warnings and precautions
The Swiss product information for Daxas® warns against
the use of roflumilast in the treatment of acute bronchos-
pasm, highlights the association with weight loss found in
the phase 3 studies M2-124 and M2-125 [38], advises cau-
tion when treating patients with a history of psychiatric
symptoms and advises against treatment of patients with a
past history of suicidal ideation or suicide attempts. Fur-
thermore, roflumilast therapy is not recommended in pa-
tients who are immunosuppressed, patients with severe
acute infections and patients with malignancy (other than
basal cell skin cancer). The US product information does
not warn against the use of roflumilast in these latter three
groups of patients.
The National Institute for Health and Clinical Excellence
(NICE, UK), which assesses newly licensed therapies for
their benefit to patients and for cost-effectiveness has re-
cently issued a guidance recommending that roflumilast
only be given “in the context of research as part of a clinic-
al trial” (http://guidance.nice.org.uk/TA244).
Current ongoing studies with
roflumilast
The “REACT” study (“Roflumilast in Chronic Obstructive
Pulmonary Disease (COPD) Patients Treated With Fixed
Combinations of Long-acting β2-agonists (LABA) and In-
haled Glucocorticosteroid (ICS)” NCT01329029) is cur-
rently recruiting patients primarily in Europe and is projec-
ted to finish in January 2014 [19]. This large randomised
trial of 1 year duration has the determination of exacer-
bation rates in patients who fulfil the current licensed in-
dication for roflumilast and are treated with either roflu-
milast or placebo as its primary end point. A similar study
(Roflumilast in Chronic Obstructive Pulmonary Disease
(COPD) Patients Treated With Fixed Dose Combinations
of Long-acting β2-agonist (LABA) and Inhaled Corticost-
eroid (ICS) NCT 01443845) is currently underway primar-
ily in the United States with estimated study completion in
May 2014 [19]. Of 33 roflumilast trials listed on clinicaltri-
als.gov, 6 are actively recruiting and two are active but not
yet recruiting COPD patients, 1 is recruiting healthy volun-
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teers for a cognition study and 1 is active but not yet re-
cruiting for an asthma study [19].
Conclusion
Roflumilast is the first-in-class phosphodiesterase 4 inhib-
itor licensed for add-on therapy in patients with moderate
to severe COPD and frequent exacerbations who are
already receiving a long-acting bronchodilator. Roflumilast
is designed to target both the systemic and pulmonary in-
flammation associated with chronic obstructive pulmonary
disease. Clinical efficacy in terms of a modest gain in
FEV1% and a reduction in exacerbation rate has been
demonstrated in phase 3 clinical trials and roflumilast has
been recently incorporated into international COPD treat-
ment guidelines. The effect of roflumilast when given as
add-on therapy to patients already taking long-acting bron-
chodilators and ICS (standard therapy) is currently not
known, however data from a large randomised controlled
trial addressing this question are expected in 2014. Data
from phase 4 post-marketing studies are required to de-
termine both the incidence and severity of adverse events
as well as the long-term beneficial effects of roflumilast
as a maintenance therapy for COPD in every-day clinical
practice.
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